DHODH-IN-23

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer. In Vitro DHODH-IN-23 (Compound A; 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM; 72 h) induces CDllb expression in THP-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: U937, HL-60, THP-1, KG-1 and MV411 Concentration: Incubation Time: 72 h Result: Inhibited cell growth with GI 50 s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively. RT-PCRCell Line: THP-1 cells Concentration: 72 h Incubation Time: 0.1, 1 and 3 μM Result: Induced CDllb mRNA expression. In Vivo DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) shows antitumor activity in MV411 mouse xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MV411 mouse xenograft model Dosage: 30 mg/kg Administration: Oral administration, twice daily for 21 days Result: Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet